tirzepatide — Dual GIP/GLP-1 receptor agonist
Dual incretin agonism — activates both GIP and GLP-1 receptors, producing greater insulin sensitivity, enhanced glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, and central appetite suppression exceeding single-agonist effects.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Dual GIP/GLP-1 receptor agonist
Mechanism of Action
Dual incretin agonism — activates both GIP and GLP-1 receptors, producing greater insulin sensitivity, enhanced glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, and central appetite suppression exceeding single-agonist effects.
Regulatory Status
FDA approved (Mounjaro for T2DM, Zepbound for weight management)
Evidence Level
High — SURMOUNT and SURPASS Phase 3 trials